Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients

Inclusion Criteria:

* Histologically/cytologically confirmed pancreatic carcinoma (locally advanced, unresectable or metastatic)
* measurable disease (at least 1 lesion accurately measured in at least 1 dimension (longest diameter as \>20mm with conventional techniques or \>10mm with spiral CT scan)
* \>=4 weeks from any major surgery
* Up to 1 prior line of gemcitabine based systemic therapy (single agent/combination therapy) for locally advanced/metastatic disease with evidence of disease progression. Prior therapy with inhibitors of angiogenesis and/or the epidermal growth factor receptor permitted. Last chemotherapy dose \>=4 weeks prior to randomization.
* May have received prior 5FU (+/- folinic acid)/gemcitabine given concurrently with radiation as a "radiation sensitizer". Last chemotherapy dose \>=4 weeks prior to randomization.
* Prior radiation treatment \>=4 weeks prior to randomization
* Age \>18 years.
* Life expectancy \>=3 months
* ECOG\< 2(Karnofsky-60%)
* leukocytes\>3,000/mcL
* absolute neutrophil count\>1,500/mcL
* platelets\>100,000/mcL
* total bilirubin \< 1.5 UNL
* AST/ALT≤2.5x institutional ULN
* creatinine within institution limits OR creatinine clearance\>60mL/min/1.73m2 for patients with creatinine levels above institution limits
* concurrent use of inhibitors/inducers of CYP3A4 are prohibited during the study treatment period
* effects of E7389 on developing human fetus are unknown. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
* Ability to understand/willingness to sign written informed consent

Exclusion Criteria:

* chemotherapy/radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
* May not be receiving other investigational agents
* Known brain metastases
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to E7389
* Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study
* Pregnant women excluded because E7389 is an antitubulin agent with the potential for teratogenic/abortifacient effects
* HIV-positive patients on combination antiretroviral therapy are ineligible because of potential for p PK interactions with E7389
* Other active malignancies in past 5 years except for cervical carcinoma in situ and non-melanomatous skin cancer